GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed Price. Currency in GBp
1,725.00
-19.20 (-1.10%)
As of 4:38PM GMT. Market open.
Stock chart is not supported by your current browser
Previous Close1,744.20
Open1,701.00
Bid1,690.00 x 0
Ask1,755.00 x 0
Day's Range1,656.80 - 1,741.20
52 Week Range1,429.80 - 1,796.40
Volume8991069
Avg. Volume8,461,651
Market Cap86B
Beta (5Y Monthly)0.37
PE Ratio (TTM)18.89
EPS (TTM)91.30
Earnings DateFeb 5, 2020
Forward Dividend & Yield0.92 (5.27%)
Ex-Dividend Date2020-02-20
1y Target Est1,644.50
  • Financial Times

    Six ways to improve the wellbeing of workers

    Contrast that with today’s understanding of how executives should tackle the stigma of mental illness at work. Richard Heron, BP’s chief medical officer, told a panel I chaired this week how the energy group’s incoming chief executive Bernard Looney had opened a dialogue about mental health. Alliance Manchester Business School’s Cary Cooper, who convened this week’s panel, pointed out that tackling stress-related illness is no longer just about providing “sushi at your desk, or mindfulness at lunch — that’s the low-hanging fruit”.

  • Biotech stocks are producing outsized gains — here’s how to get your share
    MarketWatch

    Biotech stocks are producing outsized gains — here’s how to get your share

    An evergreen strategy is to buy stocks of companies that are likely to be bought out at attractive premiums.

  • Amarin Has the Makings for a Gamechanging Product
    InvestorPlace

    Amarin Has the Makings for a Gamechanging Product

    When it comes to the biotech market, it's not easy to show consistently strong gains. But Amarin's (NASDAQ:AMRN) shareholders have come to expect a certain level of outperformance.Source: Pavel Kapysh / Shutterstock.com Just look at the average daily return for the past five years: a sizzling 84%! To put this in perspective, Netflix (NASDAQ:NFLX) has gained 44% and Facebook (NASDAQ:FB) has returned 20% during the same period.Despite all this, Amarin is not necessarily well-known. However, it definitely has an innovative team that has focused on lipid science for drug development.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis is key to Amarin's success. Its lead drug, Vascepa, is a runaway success for the biotech firm. That said, it's not without its share of risk. Vascepa Is Huge for AmarinVascepa, which is targeted for patients with high levels of triglyceride, is currently sold in the U.S., Lebanon and the United Arab Emirates. As expected, Amarin is looking to expand into other markets, including China, Canada and the Middle East.Sure, as critics have pointed out, Amarin is a one-product company that faces fierce competition, such as from GlaxoSmithKline (NYSE:GSK). Also, it looks like AstraZeneca (NYSE:AZN) will make a play for the category. While it's true that there are notable risks, the market opportunity is enormous. This means there is plenty of room for multiple players. * These 7 S&P 500 Stocks Will Deliver a Repeat Performance in the Next Decade Amarin also has the benefit of being a specialist and a long-term operator in the market. In fact, this has led to perhaps an even bigger opportunity for the company. Recent Decision May Help Amarin's CaseKeep in mind that Vascepa has shown positive results in safely lessening cardiovascular disease that goes beyond cholesterol. This is according to two landmark studies during the past couple years. And if the FDA approves to expand it -- which is expected in late December -- then it could be a gamechanger. The drug would truly be unique, and it could also represent multi-billion-dollar potential in annual revenues.Consider that in mid-November the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. FDA voted unanimously to recommend the expanded use of Vascepa. It is true that this may not a binding decision, but it carries a lot of weight.Here's what Dr. Deepak Bhatt, an executive director of the Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center, had to say:"The REDUCE-IT results are quite remarkable and illustrate how icosapent ethyl could transform the treatment of cardiovascular disease in the United States and worldwide. From my perspective as not only a researcher but also a practicing physician, icosapent ethyl represents one of the most important developments in the prevention and treatment of cardiovascular disease since statins and, if FDA approved, will be a critical tool for physicians to use to help prevent cardiovascular events such as heart attack and stroke, including fatal ones, in high-risk patients." Amarin Growth RampEven without the expanded use for Vascepa, Amarin has demonstrated an ability to scale its business. During the latest quarter, total revenue soared to $112.4 million -- a 103% increase year-over-year.A large increase in the number of new prescriptions of Vascepa is what drove this growth, including a rise in the average prescriptions per prescriber. Additionally, the company has also shown progress with its sales organization, which has seen faster-than-expected productivity from new reps.With that said, Amarin is planning to double its sales force at the beginning of 2020.Collectively, the new use of Vascepa is key as cardiovascular disease is the No. 1 killer in the U.S. with over 800,000 deaths per year . So while there are some risks, Amarin is likely to see much growth for years to come.Tom Taulli is the author of the book, Artificial Intelligence Basics: A Non-Technical Introduction. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * These 7 S&P 500 Stocks Will Deliver a Repeat Performance in the Next Decade * 7 Tech Stocks to Stuff Your Stocking With * 7 Sinfully Good Casino Stocks That Could Win the Jackpot in 2020 The post Amarin Has the Makings for a Gamechanging Product appeared first on InvestorPlace.

  • Financial Times

    Top 10 ‘intrapreneurs’: fresh faces power legal sector changes

    Justin Ergler of GlaxoSmithKline has led a corporate boycott of the billable hour in a unique demonstration of the power of business to force change on the legal industry. Meg Sullivan was hailed by judges for her success — particularly as a “non-lawyer” — in effecting change from within a conservative law firm. After joining Paul Hastings to head the US firm’s marketing and business development operations, she worked to turn sustainability and diversity into growth opportunities before they became fashionable in the wider business community.

  • Financial Times

    FT North American Innovative Lawyers Awards 2019 — winners announced

    We are pleased to reveal the winners of the FT North American Innovative Lawyer Awards 2019. They were announced at an event, pictured above, in Gotham Hall, New York, in association with research partner ...

  • Flagging French Drug Giant Tries a Familiar Remedy
    Bloomberg

    Flagging French Drug Giant Tries a Familiar Remedy

    (Bloomberg Opinion) -- Sanofi CEO Paul Hudson didn’t inherit an easy job when he took over the French pharma giant in September. The company’s shares have been in the doldrums for years, weighed down by a sagging diabetes business and a weak pipeline of new drugs. The former Novartis AG executive kicked off his turnaround effort in earnest Monday by announcing the acquisition of cancer startup Synthorx Inc. for $2.5 billion and releasing a new strategic plan for the drugmaker. Under Hudson, Sanofi plans to halt investment in heart and diabetes research, doubling down on other areas including cancer and rare diseases. The company’s consumer unit will become a stand-alone business, which raises the specter of a possible future sale. All of the moves make some sense and are in line with what other large drugmakers, including his prior employer, have tried in recent years. The key to success for Sanofi will be execution, and there are pitfalls aplenty. One of the most significant changes at Sanofi is its move away from once-core diabetes and heart medicines. Hudson says he sees more valuable opportunities elsewhere, and he could be right; pricing pressure has made those areas increasingly competitive. Sanofi’s new areas of focus may offer more growth potential and higher prices, which will be crucial if the company is going to hit Hudson’s ambitious new margin-improvement goals. Sanofi is arriving somewhat late to a shift that many of its rivals have been embracing for years, however. It has a lot of catch-up to do, and it isn’t starting with the industry’s healthiest balance sheet. A big chunk of its available cash will go to Synthorx, which is a particularly risky cornerstone for a new-look Sanofi. It makes sense that Sanofi might be interested in Synthorx’s lead product, THOR-707. That medicine and others in Synthorx’s pipeline could combine with Sanofi’s immune-boosting cancer drug Libtayo. “Could” is doing a lot of work there. Sanofi just paid one of the biggest biotech premiums of the past few years for a company that has generated little proof that its approach works. Hudson will have a hard time sufficiently stocking his pipeline if he’s paying exorbitant prices for very early-stage drugs. Selling some part of Sanofi’s multi-billion-dollar stake in Regeneron could help finance further deals, as could divesting the firm’s consumer unit. We’ll find out more about Sanofi’s over-the-counter intentions at its capital markets day Tuesday. Its preference for higher-margin products and separation of the unit certainly suggests that a sale is a possibility. Slimming down worked out well for Novartis, which has reaped billions in proceeds and a higher multiple by getting rid of consumer and eye-drug units. That doesn’t mean Sanofi will have the same experience. The 2018 sale of Novartis’s consumer arm was the result of a long-running saga that started five years earlier with a complicated asset swap with GlaxoSmithKline PLC under which it paid out more money than it got. Pfizer Inc.’s long-running effort to get rid of its over-the-counter arm ended with, you’ll never guess, a proceed-free joint-venture with GSK. The market hasn’t received Pfizer’s efforts especially kindly. It’s a positive sign that Hudson is taking action and putting his stamp on the company. But just because the strategic road he’s taking is well-trodden doesn't mean it will be easy. To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • The GlaxoSmithKline (LON:GSK) Share Price Is Up 27% And Shareholders Are Holding On
    Simply Wall St.

    The GlaxoSmithKline (LON:GSK) Share Price Is Up 27% And Shareholders Are Holding On

    Stock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking...

  • Hedge Funds Are Warming Up To GlaxoSmithKline plc  (GSK)
    Insider Monkey

    Hedge Funds Are Warming Up To GlaxoSmithKline plc (GSK)

    The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

  • Reuters

    GSK seeks FDA approval for investigational HIV treatment

    GlaxoSmithKline Plc said on Thursday its HIV unit has submitted a new drug application to the U.S. Food and Drug Administration seeking approval for fostemsavir, an experimental treatment for HIV in adults. Fostemsavir is being developed for use in combination with other antiretroviral agents in adults who have been previously taken treatments for HIV and have developed resistance to the drugs due to various factors. Antiretroviral medicines that can effectively suppress HIV have been instrumental in decreasing disease progression, HIV transmission, and AIDS-related deaths, but because of HIV's ability to constantly change, some individuals can develop viral resistance, causing their treatment regimens to fail.

  • Pfizer Stock Is A Top Pharma Company — But Should You Buy It?
    Investor's Business Daily

    Pfizer Stock Is A Top Pharma Company — But Should You Buy It?

    Pfizer stock has tumbled, below other pharmaceutical stocks. Recent news has been upbeat with a drug approval and acquisitions. But the question remains: Is Pfizer stock a buy right now?

  • Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018​
    American City Business Journals

    Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018​

    The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.

  • [video]Glaxosmithkline Could Rise 20% From Here
    TheStreet.com

    [video]Glaxosmithkline Could Rise 20% From Here

    Glaxosmithkline Plc has broken out on the upside on our Point and Figure charts. Let's check out our usual set of charts before we focus on the Point and Figure breakout. In the daily bar chart of GSK, below, we can see that prices broke out on the upside in October after an eight-month sideways consolidation pattern.

  • GuruFocus.com

    Safety Could Determine Who Wins the Next-Generation HBV Vaccine Market

    The winner of the next-generation hepatitis B vaccine market could largely be determined by upcoming safety data between Sci-B-Vac and Heplisav-B Continue reading...

  • India Plans Incentives to Bring In Foreign Manufacturers From Tesla to Glaxo
    Bloomberg

    India Plans Incentives to Bring In Foreign Manufacturers From Tesla to Glaxo

    (Bloomberg) -- Terms of Trade is a daily newsletter that untangles a world embroiled in trade wars. Sign up here. India is planning to offer 324 companies including Tesla Inc. and GlaxoSmithKline Plc incentives to set up factories in the South Asian nation in a bid to capitalize from the trade war between China and the U.S., according to a document seen by Bloomberg.The government proposes to provide the manufacturers land to set up a factory along with power, water and road access, according to draft of the document prepared by the Department for Promotion of Industry and Internal Trade and Invest India. Other companies that officials will reach out to include Eli Lilly & Co., South Korea’s Hanwha Chemical Corp., and Taiwan’s Hon Hai Precision Industry Co.While the trade war has benefited countries such as Vietnam and Malaysia, rigid land acquisition rules and labor laws have prompted investors to largely ignore India when looking for alternatives to China. The latest proposal may reduce red tape, and set the nation, which expanded at the slowest pace in six years last quarter, on a path to double its gross domestic product to $5 trillion by 2025 -- a goal set Prime Minister Narendra Modi.“While in the initial leg of relocation we have seen companies moving to Vietnam, I don’t think it is too late for India to start making an effort,” said Sonal Varma, chief economist for India and Asia-ex Japan at Nomura Holdings Inc. in Singapore. “India offers a unique advantage of being a huge domestic market too, so it is definitely an opportunity for the government to attract investment.”Under the plan, the government will create a land bank for ready-to-move-in industrial clusters, offer investment and location-based incentives and rationalize anti-dumping duties. The proposal includes incentives for plug-in and hybrid vehicles, fuel efficiency and carbon taxation. For the electronics and telecom sector, flexible employment, manufacturing-related incentives linked to investments and value addition have been sought.The country has made progress, rising 37 spots since 2017 in the World Bank’s ranking for ease of doing business, but it still comes in at 63rd, trailing not only China, but also Rwanda and Kosovo. At present, investors keen on setting up a factory need to acquire land on their own which, in some cases, involves a time consuming process of negotiating with small plot owners to part with their holding.The Prime Minister’s Office is considering the proposal and a decision is expected soon. An email sent to the spokeswoman at the commerce and industry ministry wasn’t immediately answered.Asia’s third-largest economy expanded 5% in the June quarter, with slew of data pointing to weaker economic activity.Getting investment inflows and boosting exports is therefore high on economic agenda of the government. It has already slashed corporate tax rate, making it competitive with rest of Asia, and has relaxed foreign investment rules to attract fund inflows in the country.(Updates with economist’s comment in fourth paragraph)To contact the reporter on this story: Shruti Srivastava in New Delhi at ssrivastav74@bloomberg.netTo contact the editors responsible for this story: Arijit Ghosh at aghosh@bloomberg.net, Unni KrishnanFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Reuters

    UPDATE 1-GSK sees breakthrough in shingles vaccine output in 2024

    GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production. GSK, Britain's largest drugmaker, had originally envisaged a gradual launch in the United States, its biggest market, but regulators unexpectedly recommended Shingrix not only for people reaching the age of 50 but also to replace an established product. A bioreactor complex in Belgium that makes so-called antigens - proteins that trigger an immune reaction against the shingles virus - is reaching its capacity limits.

  • Reuters

    AstraZeneca succeeds in treating lupus in late-stage study

    AstraZeneca Plc said on Monday its experimental treatment significantly reduced disease activity in patients with autoimmune disorder lupus, in a late-stage study. The results pit the British drugmaker's anifrolumab against rival GlaxoSmithKline Plc's Benlysta - the only new drug approved for lupus in the last 60 years. Benlysta recorded 473 million pounds of global sales in 2018, up 26% from a year earlier.

  • Need To Know: GlaxoSmithKline plc (LON:GSK) Insiders Have Been Selling Shares
    Simply Wall St.

    Need To Know: GlaxoSmithKline plc (LON:GSK) Insiders Have Been Selling Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

  • Thomson Reuters StreetEvents

    Edited Transcript of GSK.L earnings conference call or presentation 30-Oct-19 2:00pm GMT

    Q3 2019 GlaxoSmithKline PLC Earnings Call

  • GSK raises profit forecast after shingles vaccine sales boost
    Reuters

    GSK raises profit forecast after shingles vaccine sales boost

    The British drugmaker's shares rose as much as 3% to a more than a six-year high after the company said it now expected profit to be roughly flat at constant currency for the year, compared with a previous forecast of a fall of 3% to 5%. CEO Emma Walmsley has embarked on a plan to rejuvenate GSK, which has included the spin off or sale of a number of businesses since she took over in 2017. GSK's leaner structure has also helped the company focus more on its pharmaceuticals business and build a newer pool of treatments, including its shingles vaccine, Shingrix.

  • Reuters

    UPDATE 2-GSK raises profit forecast after shingles vaccine sales boost

    GlaxoSmithKline on Wednesday raised its annual profit forecast for the second time this year as sales of its shingles vaccine beat expectations and older medicines, including HIV treatments, continued to sell well. The British drugmaker's shares rose as much as 3% to a more than a six-year high after the company said it now expected profit to be roughly flat at constant currency for the year, compared with a previous forecast of a fall of 3% to 5%. CEO Emma Walmsley has embarked on a plan to rejuvenate GSK, which has included the spin off or sale of a number of businesses since she took over in 2017.

  • T Rowe Price Trims Microsoft, Exits Merck
    GuruFocus.com

    T Rowe Price Trims Microsoft, Exits Merck

    Fund's largest sales of the 3rd quarter Continue reading...

  • 5 Undervalued Stocks to Buy
    InvestorPlace

    5 Undervalued Stocks to Buy

    [Editor's note: "5 Undervalued Stocks to Buy" was previously published in September 2019. It has since been updated to include the most relevant information available.]Overall, the stock market continued its improvement throughout 2019, compared to where it ended in 2018; it has been a complete turnaround from last year's drop when stocks entered bear-market territory.But even though many stocks have completely erased all of their losses and made it back into the green, not all stocks have done so well. What this means is that while there are still plenty of duds out there, there are also a few undervalued stocks to buy; it has just become a little trickier to find them amid all the flashy comeback stories.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTo find the best stocks to buy now, disciplined investors might start with their own watch list, which should contain "wish list" stocks that are usually too expensive or have been put there to be on the back burner for later.Among such stocks, companies that got left out of the rally are the most compelling. Even better, some of the best undervalued stocks to buy are those that dropped by double-digit percentages during the current rally. * 7 Top-Notch REITs to Buy for Income Why is that?Stocks that have already priced in current and possible negative news typically lower the risk for investors. Such companies may work to resolve the business problem at hand, which improves its prospects and leads to a higher share price in the long run. As long as the bad news reported is a temporary setback and the business model is not broken, the risks behind buying a stock on a dip are lower.With all of that in mind, here are five undervalued stocks to buy that aren't as scary as they seem. Sony (SNE)Investors who held Sony (NYSE:SNE) stock through the Q2 2019 earnings report posted on July 30 enjoyed the rally that followed. The stock rose from $54.50 to nearly $60 recently and has been trading in the $58-$59 range ever since.The company reported revenue falling just 1.4% year-over-year but operating income rose 18%, up 35.9 billion yen (US $332.2 million), but the Q3 report doesn't look as bright.Now that Sony is trading at yearly highs, investors need not sell the stock just yet.When Sony's Playstation 5 arrives, SNE will have more power than ever. Though the PS5 release will release no sooner than mid-2020, 8K support and game refreshes should give Sony another boost in revenue when the time comes.Sony faced a few headwinds in the quarter. Contributions from first-party software titles fell. Sales of non-first party titles declined. But PS4 hardware sales rose, as did network service sales, including sales of PlayStation Plus. Celestica (CLS)In July, Celestica (NYSE:CLS) reported respectable Q3/2019 results recently, but it didn't move the CLS stock out of its $6 trading range.The company supplies equipment in ATS aerospace and defense, industrial, smart energy, health tech and capital equipment. Its enterprise unit consists of servers and storage. Why then, should investors believe the company will offset the weakness it faces in the eroding semiconductor market?Celestica is cutting costs in operations to align the business with the lower revenue. It will continue to build its capital equipment business. Management believes the fundamentals in this space will only improve in the long run. As next-generation adoption in display continues, its OLED business, for example, will add to its bottom line. * 7 Stocks to Buy With 100% Upside Potential Celestica stock is still an undervalued play worth considering. The stock may underperform a while longer and risks disappointing investors. AbbVie (ABBV)Source: Shutterstock Back when I first wrote this list of undervalued stocks, Allergan (NYSE:AGN) was the pick in this slot. And it paid off. Investors buying Allergan at the start of 2019 may have made up to $50 a share, peak to trough.In June, the stock fell below $115, only to peak at around $165 in July when my new pick, AbbVie (NYSE:ABBV), agreed to buy out the firm for $63 billion. AbbVie's rationale for acquiring Allergan is two-fold.First, it views Allergan's portfolio of products, including Botox, as attractive. Second, it has the time to use the strong cash flow from Humana to pay off its Allergan acquisition. Once Humana faces fierce competition from generics, AbbVie will have paid off much of the debt related to the AGN buyout. And in a few year's time, Allergan's drugs in the development pipeline will be ready for market.AbbVie's long-term future planning through the AGN acquisition makes AbbVie stock appealing for dividend-income investors. Even though shares rose from a $62.66 52-week low to $71.55, the stock still pays a dividend that yields 6%.At a Sep. 10 Healthcare Conference, AbbVie reiterated its commitment to cut debt and to continue growing its dividend. It will also allocate some cash for smaller mid- to late-state pipeline opportunities. Management has a good handle on integrating Allergan into its business but it will not let its existing pipeline suffer in any way.ABBV trades at an ~10% discount to the analyst price target of $79, but I think the AGN acquisition brings ABBV far more upside than that. Innoviva (INVA)Source: Shutterstock Innoviva (NASDAQ:INVA) is another stock in the drug space whose large drop starting in late January continued throughout 2019. The stock may not yet be done falling. Why not?The fall began when the FDA approved Mylan's (NASDAQ:MYL) generic version of Advair, which GlaxoSmithKline (NYSE:GSK) produces. This forced investors to worry about Innoviva's prospects because the company is paid royalties from Glaxo. In the third quarter, Innova received $65.1 million in royalty revenues from Glaxo.Investors appear to be overreacting to the generic competition. If demand for Innoviva's formulation does not drop and prices hold, royalty revenues should not fall as much as markets think, which makes INVA an ideal undervalued stock to buy now.Innoviva shares trended lower throughout 2019, as the stock lost $3 on its stock price by late-July. Investors sold the stock following the company's weak Q2 report. Innoviva reported Glaxo (NYSE:GSK) royalties falling 18% to $313.9 million. Overall, there was a net income decline of 31% (an EPS of $0.34).In its press release, the company said:"Management and the board continue to examine potential strategic actions to maximize future shareholder value." * 7 Safe Stocks to Buy and Hold Through 2020 Innoviva incurred expenses related to the evaluation of strategic options. But it will need to deliver on better shareholder value to attract stock buyers. Vodafone (VOD)Source: Apple Telecom stocks were out of favor heading into 2019. Now, telecom stocks are no longer out of favor. But Vodafone (NASDAQ:VOD), which after cratering in May, has just barely climbed back to its pre-Christmas levels. So VOD is definitely still an undervalued stock.On July 26, Vodafone reported revenue stabilizing, falling just 2.3% Y/Y (its next report was expected toward the end of October). The results sent VOD stock up 9% on the day. And ever since the stock bottomed at $16, it continues to run higher, closing recently at close to $20.In the fiscal Q1 2020 report, Vodafone said it enjoyed record low mobile contract churn. The deepening customer engagement will only strengthen as the telecom company launches 5G in all major EU markets.Service revenue in Q1 was mostly flat, down 0.2% and 0.5 pp sequentially.Simplifying the mobile plan offering will likely lead to higher revenue growth ahead. For example, Vodafone migrated 500,000 SIMs to a new unlimited offer. This will also increase ARPU and keep customers from switching to competitor services.Vodafone shares pay a dividend yield of 4.95%. If Vodafone grows its UK business as it signs on users to its 5G services and cuts costs as it signs on more customers, VOD stock will finally move higher.As of this writing, Chris Lau owned shares of Innoviva and AbbVie. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Cybersecurity Stocks to Keep Your Portfolio Safe * 7 Top-Notch REITs to Buy for Income * 5 Reasons Why I Still Believe in Hexo Stock The post 5 Undervalued Stocks to Buy appeared first on InvestorPlace.

  • Reuters

    UPDATE 2-FDA investigating whether Zantac causes carcinogens to form in users

    The U.S. Food and Drug Administration is investigating whether the popular heartburn drug Zantac causes carcinogens to form in the bodies of users, in an effort to fully understand the risks posed by the already recalled drug, the agency's spokesman said on Thursday. The issue of whether ranitidine, commonly known as Zantac, causes levels of the probable carcinogen N-nitrosodimethylamine (NDMA) to rise in users' bodies has been raised previously by Valisure, an online pharmacy that originally flagged the potential contamination of ranitidine to the FDA. Zantac, sold over-the-counter in the United States by French drugmaker Sanofi SA, and some of its generic versions, have been recalled due to possible NDMA contamination of pills that had not yet been consumed.

  • Benzinga

    The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 23.) Applied Therapeutics Inc (NASDAQ: APLT ) AVITA ...